Markets

Momenta Reveals Necuparanib Data for Pancreatic Cancer - Analyst Blog

A generic image of a person with a pen and calculator
Credit: Shutterstock photo

Momenta Pharmaceuticals, Inc. ( MNTA ) announced top-line results from the part A portion of a phase I/II study evaluating necuparanib for the treatment of advanced metastatic pancreatic cancer.

In the part A portion of the study, patients were treated with escalating doses of necuparanib (started at 0.5 mg/kg and increased via a modified 3+3 design until a maximum tolerated dose was determined) in combination with Abraxane and Gemzar. The study enrolled 37 patients.

Twelve patients treated with necuparanib plus Abraxane and Gemzar completed the first 28-day treatment cycle. They had at least one follow up CT scan and were considered eligible for evaluating radiographic response. Out of them, seven patients showed a RECIST partial response and four patients reported stable disease.

Moreover, 11 out of the 12 patients showed a more than 50% decrease in CA19.9 levels (a predictive biomarker for long-term outcome and treatment response in pancreatic cancer) from baseline. The remaining patient achieved a more than 20% decrease from baseline. Overall, disease control was achieved in 92% of these 12 patients.

Momenta intends to announce data regarding safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of necuparanib plus Abraxane and Gemzar from the part A portion of the study over the next several months.

Meanwhile, Momenta has determined a dose of necuparanib which will be used in the randomized, controlled, proof-of-concept part B portion of the study to evaluate its antitumor activity in combination with Abraxane and Gemzar, compared to treatment with both drugs without necuparanib. Momenta will start dosing patients in this portion shortly.

Necuparanib has orphan drug status in the U.S. for the treatment of pancreatic cancer.

We note that Momenta will be providing an update at its R&D meeting - apart from updating its plans regarding the development of necuparanib and other candidates, the company will provide an update on M356, Momenta's generic version of Teva's ( TEVA ) Copaxone, which is being developed in collaboration with Sandoz (a Novartis ( NVS ) company).

Momenta carries a Zacks Rank #4 (Sell). A better-ranked stock in the biotech sector is Medivation, Inc. ( MDVN ), carrying a Zacks Rank #1 (Strong Buy). Teva carries a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MEDIVATION INC (MDVN): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

MOMENTA PHARMA (MNTA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TEVA NVS

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More